Pharmacyclics LLC
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1991-01-01
- Employees
- 607
- Market Cap
- -
- Website
- http://www.pharmacyclics.com
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 59
- Registration Number
- NCT03790332
- Locations
- 🇺🇸
Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇫🇷Hôpital Robert-Debré Ap-Hp, Paris, France
🇮🇱The Edmond and Lily Safra Children's Hospital, Ramat Gan, Israel
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
- Conditions
- Mantle-Cell Lymphoma
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 352
- Registration Number
- NCT03112174
- Locations
- 🇺🇸
UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California, United States
🇺🇸The University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States
🇧🇪Institut Jules Bordet, Bruxelles, Belgium
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 193
- Registration Number
- NCT02959944
- Locations
- 🇺🇸
Emory University, Winship Cancer Institute /ID# 1140-0033, Atlanta, Georgia, United States
🇺🇸Stanford University/Stanford Cancer Center, Pasteur Drive /ID# 1140-0400, Stanford, California, United States
🇺🇸Loyola University /ID# 1140-0713, Maywood, Illinois, United States
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 445
- Registration Number
- NCT02947347
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇵🇹Centro Hospitalar do Porto - Hospital de Santo António, Porto, Portugal
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
- Conditions
- LeukemiaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 323
- Registration Number
- NCT02910583
- Locations
- 🇺🇸
University of Pennsylvania /ID# 1142-0069, Philadelphia, Pennsylvania, United States
🇦🇺St Vincent's Hospital Melbourne /ID# 1142-0501, Fitzroy, Victoria, Australia
🇺🇸Tennessee Oncology - Chattanooga /ID# 1142-0123, Chattanooga, Tennessee, United States
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
- Conditions
- Metastatic Renal Cell CarcinomaAdvanced Gastric AdenocarcinomaAdvanced Urothelial CarcinomaMetastatic Colorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 263
- Registration Number
- NCT02599324
- Locations
- 🇺🇸
Whittingham Cancer Center at Norwalk Hospital /ID# 1128-0411, Norwalk, Connecticut, United States
🇬🇧Sarah Cannon Research Institute /ID# 1128-1079, London, England, United Kingdom
🇺🇸Franciscan Health Indianapolis /ID# 1128-1125, Indianapolis, Indiana, United States
informCLLâ„¢: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 1504
- Registration Number
- NCT02582879
- Locations
- 🇺🇸
Hematology Oncology Associates Of Central New York, East Syracuse, New York, United States
🇺🇸Texas Oncology- Arlington South, Arlington, Texas, United States
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 11
- Registration Number
- NCT02548962
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 430
- Registration Number
- NCT02436668
- Locations
- 🇺🇸
Oncology Specialties, PC; Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸St. Mary's Medical Center, Daly City, California, United States
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
- Conditions
- Breast CancerNon-Small Cell Lung CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 124
- Registration Number
- NCT02403271